Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Find concise Dividend Safety insights from the three latest articles, showing payout stability and risk signals. See how income strategies affect your portfolio and retirement plans.
23 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Looking for income and potential growth in one package? This guide highlights three dividend stocks right with compel...
Amgen's dividend has powered income-focused portfolios for years, but regulatory and pricing challenges raise questio...
Income investors are eyeing bristol myers squibb's 4.3% yield, but a high payout begs questions about safety. This ar...
Vanguard’s International High Dividend Yield ETF has raised payouts in 2025 and 2026, but the durability of its forei...
Investors relying on monthly income from the Vanguard Intermediate-Term Corporate Bond Index Fund ETF are evaluating ...
As rates shift and banks adjust to a new credit environment, PFF remains the dominant preferred-stock ETF with a siza...
AMLP delivered a record May 2026 payout and a 14% trailing return, underscoring resilient midstream cash flow. Invest...
The MORT ETF offers a double-digit yield, but its payout hinges on the health of its mortgage REIT holdings. This art...
Investors face a pivotal test of yield durability in BIZD and PBDC as rate dynamics and NAV trends threaten tradition...
Investors weigh dividend safety check: aristocrats against the broad market as rates shift and AI-driven volatility f...
CNBS traders are weighing a high-conviction cannabis theme against a thin dividend base. The ETF leans on one rent-pr...